Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Hepatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
MASH and the race for liver antifibrotics
April 2026
Metabolic dysfunction-associated steatohepatitis (MASH), along with other chronic liver diseases, leads to progressive fibrosis and…
Read more
17
Mins
28 Feb 2017
The Liver Meeting 2016
The Liver Meeting 2016, held by the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts, USA, supported the…
3
Mins
15 Nov 2016
Epstein-Barr Virus: Cholestasis, Hepatitis, Or Both?
Epstein-Barr Virus (EBV), or more commonly known as the ‘kissing disease’ is seemingly unavoidable within the adolescent and teenage community.
23 Aug 2016
Cirrhosis: Reviewing the Literature and Future Perspectives
Cirrhosis is the final stage of chronic liver disease and has many causes, including viral hepatitis, excessive alcohol intake, and non-alcoholic…
23 Aug 2016
Hepatitis C: Is Regression of Advanced Fibrosis Possible After Treatment?
Liver cirrhosis represents a severe complication for hepatitis C patients. Patients with cirrhosis require immediate treatment; a sustained virological…
3
Mins
12 Jul 2016
A Call from a Patient to Openly Discuss Body Image in the Treatment of Type 1 Diabetes
Diabetes is a non-communicable disease (NCD) meaning that it often cannot be seen. After 20 years of living with Type 1 diabetes I am lucky to have no…
10
Mins
31 May 2016
Welcome to the Real World: Hepatitis C Virus Clinical Trials to Patient Realities
The symposium addressed the efficacy and safety of compounds currently available for treatment of hepatitis C virus (HCV) and chronic kidney disease…
9
Mins
31 May 2016
Editor’s Pick: Clinical, Histological, and Molecular Classification of Hepatocellular Carcinoma: How Do They Get Along?
Hepatocellular carcinoma (HCC) will soon become a prominent part of the medical and economic burden on many Western countries’ healthcare systems.
5
Mins
31 May 2016
The International Liver Congress (ILC) 2016: Rifaximin Use in Cirrhosis-Related Hepatological Disorders and New Perspectives
Rifaximin (RFX)-α is a broad-spectrum antibiotic that targets commensal gut bacteria and reduces the excess ammonia produced by the gut bacteria of…
Loading posts...
« Previous
1
…
11
12
13
14
15
…
19
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View